What does the evidence say about Berberine Cholesterol Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Berberine Cholesterol Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. [Zhao Jie V. (2026); evidence level 2] - Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. [Zhao Jie V. (2026); evidence level 2] - Despite of the benefits on lipid profile and glucose metabolism, the effect of berberine on the risk of IHD and diabetes has not been clarified. [Zhao Jie V. (2026); evidence level 2] - 1 2 3 4 Ischemic heart disease (IHD) is the single leading cause of mortality and poses a heavy burden on healthcare, which accounts for ~16% of all deaths globally. [Zhao Jie V. (2026); evidence level 2] - The primary prevention of CVD through the management of dyslipidemia, a major risk factor for CVD, is a critical strategy for improving population health outcomes and reducing the associated economic impact. [Xia Yuanqing (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.